Accumulation of HIV-1 Drug Resistance Mutations after First-Line Immunological Failure to Evaluate the Options of Recycling NRTI Drugs in Second-Line Treatment: A Study from South India

Sathasivam Sivamalar, Thongadi Ramesh Dinesha, Selvamurthi Gomathi, Ambrose Pradeep, Jayaseelan Boobalan, Sunil Solomon, Selvamuthu Poongulali, Suniti Solomon, Pachamuthu Balakrishnan, Shanmugam Saravanan

Research output: Contribution to journalArticle

Abstract

Lack of HIV-1 viral load monitoring in resource-limited settings leads to the development of HIV drug resistance mutations, although WHO recommends viral load testing for monitoring as this helps in preserving future treatment options and also avoid unnecessary switching to more expensive drugs. A total of 101 patients attaining first-line treatment failure (FTF) were followed until second-line treatment failure (STF) to study the rate of accumulation of thymidine analogue mutations (TAMs), their future drug options, and genetic evolution. The result shows that predominant nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations were M184V/I (87.3% in FTF and 79% in STF) followed by TAMs (53.4% in FTF and 54.5% in STF). The rate of accumulation of TAMs was higher for a patient with TAMI [0.015 TAM per person-month (TPPM)], TAMII (0.042 TPPM), and 1 (0.005 TPPM) or 2 TAMs (0.008 TPPM) compared with a patient with both TAMs and 3 or >3 TAMs. Future ART options show that >50% of the patients can be considered for choices to recycle NRTIs in the second-line, and third-line therapy. We conclude that the patients who initiated thymidine analogue-based first-line before 2010 can be very well opted for AZT- and TDF-based second-line regimen in the future.

Original languageEnglish (US)
Pages (from-to)271-274
Number of pages4
JournalAIDS Research and Human Retroviruses
Volume33
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Recycling
Drug Resistance
HIV-1
India
Thymidine
Treatment Failure
Mutation
Pharmaceutical Preparations
Therapeutics
Viral Load
Reverse Transcriptase Inhibitors
Molecular Evolution
HIV

Keywords

  • first-line
  • HIV drug resistance
  • resistance mutation in India
  • second-line
  • TAMs

ASJC Scopus subject areas

  • Immunology
  • Infectious Diseases
  • Virology

Cite this

Accumulation of HIV-1 Drug Resistance Mutations after First-Line Immunological Failure to Evaluate the Options of Recycling NRTI Drugs in Second-Line Treatment : A Study from South India. / Sivamalar, Sathasivam; Dinesha, Thongadi Ramesh; Gomathi, Selvamurthi; Pradeep, Ambrose; Boobalan, Jayaseelan; Solomon, Sunil; Poongulali, Selvamuthu; Solomon, Suniti; Balakrishnan, Pachamuthu; Saravanan, Shanmugam.

In: AIDS Research and Human Retroviruses, Vol. 33, No. 3, 01.03.2017, p. 271-274.

Research output: Contribution to journalArticle

Sivamalar, Sathasivam ; Dinesha, Thongadi Ramesh ; Gomathi, Selvamurthi ; Pradeep, Ambrose ; Boobalan, Jayaseelan ; Solomon, Sunil ; Poongulali, Selvamuthu ; Solomon, Suniti ; Balakrishnan, Pachamuthu ; Saravanan, Shanmugam. / Accumulation of HIV-1 Drug Resistance Mutations after First-Line Immunological Failure to Evaluate the Options of Recycling NRTI Drugs in Second-Line Treatment : A Study from South India. In: AIDS Research and Human Retroviruses. 2017 ; Vol. 33, No. 3. pp. 271-274.
@article{7b8bc3b3a9b9443da6f538d423a8a983,
title = "Accumulation of HIV-1 Drug Resistance Mutations after First-Line Immunological Failure to Evaluate the Options of Recycling NRTI Drugs in Second-Line Treatment: A Study from South India",
abstract = "Lack of HIV-1 viral load monitoring in resource-limited settings leads to the development of HIV drug resistance mutations, although WHO recommends viral load testing for monitoring as this helps in preserving future treatment options and also avoid unnecessary switching to more expensive drugs. A total of 101 patients attaining first-line treatment failure (FTF) were followed until second-line treatment failure (STF) to study the rate of accumulation of thymidine analogue mutations (TAMs), their future drug options, and genetic evolution. The result shows that predominant nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations were M184V/I (87.3{\%} in FTF and 79{\%} in STF) followed by TAMs (53.4{\%} in FTF and 54.5{\%} in STF). The rate of accumulation of TAMs was higher for a patient with TAMI [0.015 TAM per person-month (TPPM)], TAMII (0.042 TPPM), and 1 (0.005 TPPM) or 2 TAMs (0.008 TPPM) compared with a patient with both TAMs and 3 or >3 TAMs. Future ART options show that >50{\%} of the patients can be considered for choices to recycle NRTIs in the second-line, and third-line therapy. We conclude that the patients who initiated thymidine analogue-based first-line before 2010 can be very well opted for AZT- and TDF-based second-line regimen in the future.",
keywords = "first-line, HIV drug resistance, resistance mutation in India, second-line, TAMs",
author = "Sathasivam Sivamalar and Dinesha, {Thongadi Ramesh} and Selvamurthi Gomathi and Ambrose Pradeep and Jayaseelan Boobalan and Sunil Solomon and Selvamuthu Poongulali and Suniti Solomon and Pachamuthu Balakrishnan and Shanmugam Saravanan",
year = "2017",
month = "3",
day = "1",
doi = "10.1089/aid.2016.0070",
language = "English (US)",
volume = "33",
pages = "271--274",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Accumulation of HIV-1 Drug Resistance Mutations after First-Line Immunological Failure to Evaluate the Options of Recycling NRTI Drugs in Second-Line Treatment

T2 - A Study from South India

AU - Sivamalar, Sathasivam

AU - Dinesha, Thongadi Ramesh

AU - Gomathi, Selvamurthi

AU - Pradeep, Ambrose

AU - Boobalan, Jayaseelan

AU - Solomon, Sunil

AU - Poongulali, Selvamuthu

AU - Solomon, Suniti

AU - Balakrishnan, Pachamuthu

AU - Saravanan, Shanmugam

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Lack of HIV-1 viral load monitoring in resource-limited settings leads to the development of HIV drug resistance mutations, although WHO recommends viral load testing for monitoring as this helps in preserving future treatment options and also avoid unnecessary switching to more expensive drugs. A total of 101 patients attaining first-line treatment failure (FTF) were followed until second-line treatment failure (STF) to study the rate of accumulation of thymidine analogue mutations (TAMs), their future drug options, and genetic evolution. The result shows that predominant nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations were M184V/I (87.3% in FTF and 79% in STF) followed by TAMs (53.4% in FTF and 54.5% in STF). The rate of accumulation of TAMs was higher for a patient with TAMI [0.015 TAM per person-month (TPPM)], TAMII (0.042 TPPM), and 1 (0.005 TPPM) or 2 TAMs (0.008 TPPM) compared with a patient with both TAMs and 3 or >3 TAMs. Future ART options show that >50% of the patients can be considered for choices to recycle NRTIs in the second-line, and third-line therapy. We conclude that the patients who initiated thymidine analogue-based first-line before 2010 can be very well opted for AZT- and TDF-based second-line regimen in the future.

AB - Lack of HIV-1 viral load monitoring in resource-limited settings leads to the development of HIV drug resistance mutations, although WHO recommends viral load testing for monitoring as this helps in preserving future treatment options and also avoid unnecessary switching to more expensive drugs. A total of 101 patients attaining first-line treatment failure (FTF) were followed until second-line treatment failure (STF) to study the rate of accumulation of thymidine analogue mutations (TAMs), their future drug options, and genetic evolution. The result shows that predominant nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations were M184V/I (87.3% in FTF and 79% in STF) followed by TAMs (53.4% in FTF and 54.5% in STF). The rate of accumulation of TAMs was higher for a patient with TAMI [0.015 TAM per person-month (TPPM)], TAMII (0.042 TPPM), and 1 (0.005 TPPM) or 2 TAMs (0.008 TPPM) compared with a patient with both TAMs and 3 or >3 TAMs. Future ART options show that >50% of the patients can be considered for choices to recycle NRTIs in the second-line, and third-line therapy. We conclude that the patients who initiated thymidine analogue-based first-line before 2010 can be very well opted for AZT- and TDF-based second-line regimen in the future.

KW - first-line

KW - HIV drug resistance

KW - resistance mutation in India

KW - second-line

KW - TAMs

UR - http://www.scopus.com/inward/record.url?scp=85014502407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014502407&partnerID=8YFLogxK

U2 - 10.1089/aid.2016.0070

DO - 10.1089/aid.2016.0070

M3 - Article

C2 - 27460519

AN - SCOPUS:85014502407

VL - 33

SP - 271

EP - 274

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 3

ER -